INV-6452 / Ionova Life Sci - LARVOL DELTA

Discovery of INV-6452, a CDK2/4 inhibitor for the treatment of HR-positive HER2-negative breast cancer resistant to current CDK4/6 therapy (AACR 2025) - "CDK4/6 Inhibitors represented by palbociclib, ribociclib, abemaciclib and dalpiciclib, working through their inhibitory activities toward G1/S transition cyclin-dependent protein kinases 4 and 6 coupled with cyclins D1 and D3, have emerged as one of the mainstream therapies for HR positive HER2 negative breast cancer. Additionally, INV-6452 had a limited impact on the proliferation and myeloid-specific differentiation of human hematopoietic stem and progenitor cells. The promising profiles of INV-6452 suggest its potential in addressing unmet medical needs, and its clinical development is being planned."

Late-breaking abstract • Breast Cancer • Endometrial Cancer • Eye Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • CDK1 • CDK4 • CDK9 • HER-2